Selected research
Industry Research
Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Research Report 2026
Market perspective
The global Hypoxia Inducible Factor 1 Alpha Inhibitor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hypoxia Inducible Factor 1 Alpha Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hypoxia Inducible Factor 1 Alpha Inhibitor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hypoxia Inducible Factor 1 Alpha Inhibitor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hypoxia Inducible Factor 1 Alpha Inhibitor include Vascular Biogenics Ltd., Transcriptogen Ltd, Sorrento Therapeutics, Inc., RXi Pharmaceuticals Corporation, Peloton Therapeutics, Inc., OncoImmune, Inc., InterMed Discovery GmbH, F. Hoffmann-La Roche Ltd. and Cerulean Pharma, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hypoxia Inducible Factor 1 Alpha Inhibitor market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hypoxia Inducible Factor 1 Alpha Inhibitor Market by Company
Vascular Biogenics Ltd.
Transcriptogen Ltd
Sorrento Therapeutics, Inc.
RXi Pharmaceuticals Corporation
Peloton Therapeutics, Inc.
OncoImmune, Inc.
InterMed Discovery GmbH
F. Hoffmann-La Roche Ltd.
Cerulean Pharma, Inc.
CASI Pharmaceuticals Inc.
Aileron Therapeutics, Inc.
Hypoxia Inducible Factor 1 Alpha Inhibitor Segment by Type
CRLX-101
CASI-2ME2
BC-001
Others
Hypoxia Inducible Factor 1 Alpha Inhibitor Segment by Application
Solid Tumor
Colorectal Cancer
Acute Myelocytic Leukemia
Others
Hypoxia Inducible Factor 1 Alpha Inhibitor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hypoxia Inducible Factor 1 Alpha Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hypoxia Inducible Factor 1 Alpha Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hypoxia Inducible Factor 1 Alpha Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hypoxia Inducible Factor 1 Alpha Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hypoxia Inducible Factor 1 Alpha Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hypoxia Inducible Factor 1 Alpha Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CRLX-101
- CASI-2ME2
- BC-001
- Others
Applications
- Solid Tumor
- Colorectal Cancer
- Acute Myelocytic Leukemia
- Others
Companies covered
- Vascular Biogenics Ltd.
- Transcriptogen Ltd
- Sorrento Therapeutics, Inc.
- RXi Pharmaceuticals Corporation
- Peloton Therapeutics, Inc.
- OncoImmune, Inc.
- InterMed Discovery GmbH
- F. Hoffmann-La Roche Ltd.
- Cerulean Pharma, Inc.
- CASI Pharmaceuticals Inc.
- Aileron Therapeutics, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size (2021-2032)
- 2.2.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales (2021-2032)
- 2.2.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Average Price (2021-2032)
- 2.3 Hypoxia Inducible Factor 1 Alpha Inhibitor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 CRLX-101
- 2.3.3 CASI-2ME2
- 2.3.4 BC-001
- 2.3.5 Others
- 2.4 Hypoxia Inducible Factor 1 Alpha Inhibitor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Solid Tumor
- 2.4.3 Colorectal Cancer
- 2.4.4 Acute Myelocytic Leukemia
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue of Manufacturers (2021-2026)
- 3.4 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Average Price by Manufacturers (2021-2026)
- 3.5 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hypoxia Inducible Factor 1 Alpha Inhibitor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hypoxia Inducible Factor 1 Alpha Inhibitor, Product Type & Application
- 3.8 Global Manufacturers of Hypoxia Inducible Factor 1 Alpha Inhibitor, Established Date
- 3.9 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Vascular Biogenics Ltd.
- 4.1.1 Vascular Biogenics Ltd. Company Information
- 4.1.2 Vascular Biogenics Ltd. Business Overview
- 4.1.3 Vascular Biogenics Ltd. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Vascular Biogenics Ltd. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.1.5 Vascular Biogenics Ltd. Recent Developments
- 4.2 Transcriptogen Ltd
- 4.2.1 Transcriptogen Ltd Company Information
- 4.2.2 Transcriptogen Ltd Business Overview
- 4.2.3 Transcriptogen Ltd Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Transcriptogen Ltd Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.2.5 Transcriptogen Ltd Recent Developments
- 4.3 Sorrento Therapeutics, Inc.
- 4.3.1 Sorrento Therapeutics, Inc. Company Information
- 4.3.2 Sorrento Therapeutics, Inc. Business Overview
- 4.3.3 Sorrento Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sorrento Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.3.5 Sorrento Therapeutics, Inc. Recent Developments
- 4.4 RXi Pharmaceuticals Corporation
- 4.4.1 RXi Pharmaceuticals Corporation Company Information
- 4.4.2 RXi Pharmaceuticals Corporation Business Overview
- 4.4.3 RXi Pharmaceuticals Corporation Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 RXi Pharmaceuticals Corporation Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.4.5 RXi Pharmaceuticals Corporation Recent Developments
- 4.5 Peloton Therapeutics, Inc.
- 4.5.1 Peloton Therapeutics, Inc. Company Information
- 4.5.2 Peloton Therapeutics, Inc. Business Overview
- 4.5.3 Peloton Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Peloton Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.5.5 Peloton Therapeutics, Inc. Recent Developments
- 4.6 OncoImmune, Inc.
- 4.6.1 OncoImmune, Inc. Company Information
- 4.6.2 OncoImmune, Inc. Business Overview
- 4.6.3 OncoImmune, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 OncoImmune, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.6.5 OncoImmune, Inc. Recent Developments
- 4.7 InterMed Discovery GmbH
- 4.7.1 InterMed Discovery GmbH Company Information
- 4.7.2 InterMed Discovery GmbH Business Overview
- 4.7.3 InterMed Discovery GmbH Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 InterMed Discovery GmbH Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.7.5 InterMed Discovery GmbH Recent Developments
- 4.8 F. Hoffmann-La Roche Ltd.
- 4.8.1 F. Hoffmann-La Roche Ltd. Company Information
- 4.8.2 F. Hoffmann-La Roche Ltd. Business Overview
- 4.8.3 F. Hoffmann-La Roche Ltd. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 F. Hoffmann-La Roche Ltd. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.8.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 4.9 Cerulean Pharma, Inc.
- 4.9.1 Cerulean Pharma, Inc. Company Information
- 4.9.2 Cerulean Pharma, Inc. Business Overview
- 4.9.3 Cerulean Pharma, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Cerulean Pharma, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.9.5 Cerulean Pharma, Inc. Recent Developments
- 4.10 CASI Pharmaceuticals Inc.
- 4.10.1 CASI Pharmaceuticals Inc. Company Information
- 4.10.2 CASI Pharmaceuticals Inc. Business Overview
- 4.10.3 CASI Pharmaceuticals Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 CASI Pharmaceuticals Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.10.5 CASI Pharmaceuticals Inc. Recent Developments
- 4.11 Aileron Therapeutics, Inc.
- 4.11.1 Aileron Therapeutics, Inc. Company Information
- 4.11.2 Aileron Therapeutics, Inc. Business Overview
- 4.11.3 Aileron Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Aileron Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
- 4.11.5 Aileron Therapeutics, Inc. Recent Developments
5 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Scenario by Region
- 5.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Region: 2021-2032
- 5.2.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Region: 2021-2026
- 5.2.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Region: 2027-2032
- 5.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Region: 2021-2032
- 5.3.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Region: 2021-2026
- 5.3.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Region: 2027-2032
- 5.4 North America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Facts & Figures by Country
- 5.4.1 North America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Country (2021-2032)
- 5.4.3 North America Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Market Facts & Figures by Country
- 5.5.1 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Country (2021-2032)
- 5.5.3 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Facts & Figures by Country
- 5.7.1 South America Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Country (2021-2032)
- 5.7.3 South America Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Type (2021-2032)
- 6.1.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Market Share by Type (2021-2032)
- 6.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Type (2021-2032)
- 6.2.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue Market Share by Type (2021-2032)
- 6.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Application (2021-2032)
- 7.1.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Market Share by Application (2021-2032)
- 7.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Application (2021-2032)
- 7.2.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue Market Share by Application (2021-2032)
- 7.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hypoxia Inducible Factor 1 Alpha Inhibitor Value Chain Analysis
- 8.1.1 Hypoxia Inducible Factor 1 Alpha Inhibitor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hypoxia Inducible Factor 1 Alpha Inhibitor Production Mode & Process
- 8.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Distributors
- 8.2.3 Hypoxia Inducible Factor 1 Alpha Inhibitor Customers
9 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Analyzing Market Dynamics
- 9.1 Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Trends
- 9.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Drivers
- 9.3 Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Opportunities and Challenges
- 9.4 Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst